The field of prostate cancer has witnessed incredible progress in the last decade, owing to the approval of multiple survival-prolonging treatments for metastatic castration-resistant prostate cancer (mCRPC).
Enzalutamide is a nonsteroidal androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling axis. It has been approved for the treatment of mCRPC both in the postdocetaxel and in the chemotherapy-naive settings. We summarize the milestones in the development of enzalutamide in patients with prostate cancer. Special focus is placed on the results of the STRIVE Phase II clinical trial comparing head to head enzalutamide and bicalutamide in patients with nonmetastatic and mCRPC who have failed androgen deprivation and in other ongoing trials in the same setting and in earlier disease phases.
Future oncology (London, England). 2016 Feb 03 [Epub ahead of print]
Rosa Nadal, Joaquim Bellmunt
Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA. , Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.